The Insider Jason Cole Unloaded 1129 shares of bluebird bio, Inc. (BLUE); 3 Analysts Are Bullish Opus Bank (OPB) Last Week

Chief Legal Officer Jason Cole of Bluebird Bio Inc, sold some 1,129 of the ‘s company shares worth $195,741 USD with an average of $173.4 per share. The chance of this transaction remaining undiscovered is extremely low because it’s new, with Jason Cole now holding 19,798 shares — that is 0.04% of Bluebird Bio Inc’s stock market capitalization.

Among 8 analysts covering Opus Bank (NASDAQ:OPB), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Opus Bank had 16 analyst reports since July 29, 2015 according to SRatingsIntel. Sandler O’Neill downgraded the stock to “Hold” rating in Thursday, October 20 report. Keefe Bruyette & Woods maintained Opus Bank (NASDAQ:OPB) on Thursday, December 21 with “Hold” rating. The stock of Opus Bank (NASDAQ:OPB) earned “Mkt Perform” rating by Keefe Bruyette & Woods on Tuesday, October 25. The stock of Opus Bank (NASDAQ:OPB) earned “Market Perform” rating by Hovde Group on Monday, January 30. JMP Securities initiated the stock with “Mkt Perform” rating in Friday, September 16 report. The stock of Opus Bank (NASDAQ:OPB) has “Buy” rating given on Monday, July 10 by Piper Jaffray. Keefe Bruyette & Woods maintained it with “Hold” rating and $24.0 target in Sunday, August 27 report. The company was maintained on Thursday, October 5 by Piper Jaffray. The firm has “Neutral” rating given on Monday, January 30 by JP Morgan. Hovde Group maintained the stock with “Outperform” rating in Monday, December 19 report. See Opus Bank (NASDAQ:OPB) latest ratings:

21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $29.0 Maintain
05/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $27.0 Maintain
27/08/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $24.0 Maintain
10/07/2017 Broker: Piper Jaffray Rating: Buy New Target: $27.0000 Maintain

Opus Bank provides various banking products, services, and solutions for small to mid-sized companies, entrepreneurs, real estate investors, professionals, and high net worth individuals. The company has market cap of $1.01 billion. It offers demand deposits, checking accounts, money market accounts, savings accounts, and certificates of deposit. It has a 38.12 P/E ratio. The firm also provides multifamily residential loans, commercial real estate loans, commercial business loans, small business administration loans, construction loans, and single-family residential and consumer loans; and loans and lines for working capital, expansion, acquisitions, consolidation, and transition.

The stock increased 1.80% or $0.5 during the last trading session, reaching $28.25. About 182,442 shares traded. Opus Bank (NASDAQ:OPB) has declined 39.11% since January 9, 2017 and is downtrending. It has underperformed by 55.81% the S&P500.

Since August 1, 2017, it had 0 insider buys, and 25 insider sales for $46.62 million activity. $277,099 worth of bluebird bio, Inc. (NASDAQ:BLUE) was sold by Davidson David. On Friday, October 20 the insider Leschly Nick sold $1.02M. 861 shares valued at $80,787 were sold by Sullivan Eric on Thursday, August 3. 9,900 shares valued at $2.14M were sold by Walsh Jeffrey T. on Monday, December 11. 7,000 shares valued at $1.52 million were sold by Vachon Mark on Monday, December 11. 2,250 shares were sold by Gregory Philip D, worth $296,602. On Monday, August 14 the insider Mandell James sold $95,950.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $8.31 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

Investors sentiment increased to 1.79 in Q3 2017. Its up 0.11, from 1.68 in 2017Q2. It improved, as 35 investors sold bluebird bio, Inc. shares while 42 reduced holdings. 45 funds opened positions while 93 raised stakes. 49.05 million shares or 2.37% more from 47.91 million shares in 2017Q2 were reported. 71,329 were accumulated by Nicholas Inv Prtnrs Lp. Artal accumulated 135,000 shares or 0.32% of the stock. Ameriprise Financial owns 340,259 shares for 0.02% of their portfolio. Capital, California-based fund reported 1.13M shares. Metropolitan Life Insurance owns 30,518 shares or 0.03% of their US portfolio. Amer Century stated it has 0.03% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Gam Holding Ag has invested 0.23% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Cormorant Asset Limited owns 137,500 shares or 3.33% of their US portfolio. Armistice Llc invested in 0.61% or 38,000 shares. Teacher Retirement Of Texas invested 0% in bluebird bio, Inc. (NASDAQ:BLUE). Deutsche Bancshares Ag owns 258,103 shares or 0.02% of their US portfolio. Gotham Asset Mngmt Lc has invested 0.12% in bluebird bio, Inc. (NASDAQ:BLUE). The Massachusetts-based Panagora Asset Mgmt Incorporated has invested 0% in bluebird bio, Inc. (NASDAQ:BLUE). Raymond James Ser Advsrs owns 2,202 shares or 0% of their US portfolio. Eventide Asset Mngmt Limited Liability holds 3.21% or 412,000 shares.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on February, 28. They expect $-1.63 EPS, up 13.30% or $0.25 from last year’s $-1.88 per share. After $-1.73 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -5.78% EPS growth.

The stock decreased 0.35% or $0.6 during the last trading session, reaching $169.5. About 902,966 shares traded or 1.97% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has risen 112.34% since January 9, 2017 and is uptrending. It has outperformed by 95.64% the S&P500.